GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allogene Therapeutics Inc (NAS:ALLO) » Definitions » 14-Day RSI

ALLO (Allogene Therapeutics) 14-Day RSI : 48.58 (As of Mar. 17, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Allogene Therapeutics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2025-03-17), Allogene Therapeutics's 14-Day RSI is 48.58.

The industry rank for Allogene Therapeutics's 14-Day RSI or its related term are showing as below:

ALLO's 14-Day RSI is ranked worse than
62.87% of 1519 companies
in the Biotechnology industry
Industry Median: 45.28 vs ALLO: 48.58

Competitive Comparison of Allogene Therapeutics's 14-Day RSI

For the Biotechnology subindustry, Allogene Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allogene Therapeutics's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allogene Therapeutics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Allogene Therapeutics's 14-Day RSI falls into.



Allogene Therapeutics  (NAS:ALLO) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allogene Therapeutics  (NAS:ALLO) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Allogene Therapeutics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Allogene Therapeutics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Allogene Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
210 East Grand Avenue, South San Francisco, CA, USA, 94080
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
Executives
Earl Martin Douglas officer: GENERAL COUNSEL BIOMIMETIC THERAPEUTICS, INC., 389 NICHOL MILL LANE, FRANKLIN TN 37067
Zachary Roberts officer: EVP of R&D C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
David D Chang director, officer: President and CEO C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Geoffrey M. Parker officer: CHIEF FINANCIAL OFFICER 15 RIORDAN PLACE, MENLO PARK CA 94025
Timothy L. Moore officer: Chief Technical Officer C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Deborah M. Messemer director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Franz B Humer director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
Arie Belldegrun director, 10 percent owner UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Yinlin Jack Chen officer: SVP, Finance 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Lillian Smith officer: VP, Corporate Counsel 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Veer Bhavnagri officer: General Counsel C/O ALLOGENE THERAPEUTICS, INC., 210 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Owen N. Witte director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Rafael Amado officer: EVP of R&D and CMO 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Alison Moore officer: Chief Technical Officer C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080